Wall Street analyst estimates for BrainsWay Ltd. (BWAY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-10 | $0.12 | ||
| 2026-08-12 | $0.14 | $0.10 | +40.0% |
| 2026-05-13 | $0.12 | $0.05 | +140.0% |
| 2026-03-11 | $0.14 | $0.06 | +133.3% |
| 2025-11-11 | $0.04 | $0.05 | -20.0% |
| 2025-08-13 | $0.05 | $0.04 | +25.0% |
| 2025-05-13 | $0.02 | $0.01 | +100.0% |
| 2025-03-11 | $0.04 | $0.03 | +33.3% |
Valuation Ratios
| P/E Ratio | 54.41 |
| Price / Book | 6.67 |
| EV / EBITDA | 73.40 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.1M | $16.4M | $23.1M | $22.1M | $29.7M | $27.2M | $31.8M | $41.0M | $52.2M |
| Cost of Revenue | $2.4M | $2.6M | $3.6M | $5.1M | $5.1M | $6.6M | $7.1M | $8.3M | $10.4M | $12.8M |
| Gross Profit | $9.1M | $8.6M | $12.8M | $18.0M | $17.0M | $23.1M | $20.0M | $23.5M | $30.6M | $39.4M |
| Research & Development | $3.8M | $5.3M | $6.2M | $7.9M | $5.8M | $6.4M | $7.7M | $6.7M | $7.2M | $9.6M |
| Selling, General & Admin | $6.9M | $9.3M | $11.3M | $17.7M | $16.0M | $21.7M | $25.1M | $21.6M | $22.0M | $25.5M |
| Operating Expenses | $11.2M | $15.2M | $17.9M | $26.4M | $21.8M | $28.1M | $32.7M | $28.4M | $29.2M | $35.1M |
| Operating Income | -$2.1M | -$6.6M | -$5.1M | -$8.5M | -$4.8M | -$5.0M | -$12.7M | -$5.0M | $1.4M | $4.3M |
| EBITDA | -$1.3M | -$5.6M | -$4.4M | -$6.7M | -$3.5M | -$4.7M | -$11.5M | -$2.6M | $5.4M | $11.5M |
| Interest Expense | $61000 | $134000 | $395000 | $506000 | $106000 | $141000 | $68000 | $298000 | $1.4M | $2.2M |
| Pre-tax Income | -$2.4M | -$6.9M | -$6.3M | -$9.9M | -$5.1M | -$6.4M | -$13.0M | -$3.9M | $3.5M | $7.7M |
| Income Tax | 0 | $169000 | $209000 | $422000 | $237000 | $43000 | $315000 | $251000 | $538000 | $77000 |
| Net Income | -$2.4M | -$7.1M | -$6.5M | -$10.3M | -$5.4M | -$6.5M | -$13.3M | -$4.2M | $2.9M | $7.6M |
| EPS | $-0.17 | $-0.48 | $-0.39 | $-0.50 | $-0.24 | $-0.21 | $-0.43 | $-0.13 | $0.09 | $0.40 |
| EPS (Diluted) | $-0.17 | $-0.48 | $-0.39 | $-0.50 | $-0.24 | $-0.21 | $-0.43 | $-0.13 | $0.09 | $0.36 |
| Shares Outstanding (Diluted) | $14.5M | $14.8M | $16.6M | $20.5M | $22.5M | $31.2M | $33.0M | $33.2M | $34.8M | $21.2M |
Price
| Price | $13.46 |
| Market Cap | $528M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: CERS · CVRX · DCTH · MASS · NPCE · RXST · SENS
Explore sector: Healthcare · Medical - Specialties
More sections of BWAY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks